Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial

Shimada, Kazuyuki; Yamaguchi, Motoko; Atsuta, Yoshiko; Matsue, Kosei; Sato, Keijiro; Kusumoto, Shigeru; Nagai, Hirokazu; Takizawa, Jun; Fukuhara, Noriko; Nagafuji, Koji; Miyazaki, Kana; Ohtsuka, Eiichi; Okamoto, Masanori; Sugita, Yoshiaki; Uchida, Toshiki; Kayukawa, Satoshi; Wake, Atsushi; Ennishi, Daisuke; Kondo, Yukio; Izumi, Tohru; Kin, Yoshihiro; Tsukasaki, Kunihiro; Hashimoto, Daigo; Yuge, Masaaki; Yanagisawa, Atsumi; Kuwatsuka, Yachiyo; Shimada, Satoko; Yasukawa, Masaki; Niitsu, Nozomi; Kiyoi, Hitoshi; Suzuki, Ritsuro; Tokunaga, Takashi; Nakamura, Shigeo; Kinoshita, Tomohiro

doi:10.1016/s1470-2045(20)30059-0

Cited by 63 publications

(64 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hypokalemia caused by rituximab administration has never been reported in the literature so far. Hypokalemia was reported as a rare adverse event of complex chemo-immunotherapy combinations for lymphoma treatment (Polprasert et al, 2011;Budde et al, 2013;Johnston et al, 2016;Godfrey et al, 2019;Shimada et al, 2020). However, none of these reports suggested a direct link between rituximab administration and hypokalemia.…”

Section: Discussionmentioning

confidence: 99%

Hypokalemia After Rituximab Administration in Steroid-Dependent Nephrotic Syndrome: A Case Report

et al. 2020

View full text Add to dashboard Cite

The monoclonal antibody rituximab is a commonly used steroid sparing agent for steroiddependent idiopathic nephrotic syndrome of childhood. With this brief report, we describe the first case of symptomatic hypokalemia after intravenous rituximab administration in a young woman. The sudden onset of dizziness and palpitation prompted acute lifethreatening hypokalemia recognition by blood gas analysis and electrocardiography. Her symptoms were rapidly controlled by intravenous potassium administration. Such adverse drug reactions, when mild and self-limiting, can easily be overlooked if not expected or investigated. Health professionals should take into account the possibility of acute hypokalemia after rituximab administration in order to promptly setup the appropriate treatment and limit potentially severe complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Hypokalemia After Rituximab Administration in Steroid-Dependent Nephrotic Syndrome: A Case Report

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Besides recurrent stroke episodes, seizures, myoclonus, meningoradiculitis, PNS sensory and motor deficits, or neuropathies, 74 may be present 75 with a wide spectrum of clinical pictures from acute polyradiculoneuropathy 76 to multiple mononeuropathy, 77 or demyelinating polyneuropathy 78 . The prognosis of the intravascular lymphoma is usually poor, but has been improved by rituximab‐based chemotherapy combined with high‐dose methotrexate and intrathecal chemotherapy 79 . However, a significant proportion of patients relapse, especially those with CNS manifestations 70 .…”

Section: Non‐hodgkin Lymphoma‐related Peripheral Neuropathiesmentioning

confidence: 99%

From pathogenesis to personalized treatments of neuropathies in hematological malignancies

Briani

Visentin

Cerri³

et al. 2020

J Peripheral Nervous Sys

View full text Add to dashboard Cite

The peripheral nervous system may be involved at any stage in the course of several hematological diseases, the most common being monoclonal gammopathies (of undetermined significance or malignant) or lymphomas. The underlying pathogenic mechanisms are different and therapies aim at targeting the dangerous either B‐cell or plasma cell clones. Recently, high‐throughput technologies, and next‐generation sequencing have increased our knowledge of hematological diseases pathogenesis by the identification of somatic mutation affecting pivotal signaling pathways. Accordingly, new target therapies are used that may also be borrowed for treatment of neuropathies in hematological diseases.

show abstract

“…10,11 Evidence has suggested that several natural drugs, for example, vincristine, taxanes and camptothecin, are effective anti-tumour agents. [12][13][14] Furthermore, some natural compounds have been demonstrated to own anti-tumour effects on OS cell lines with few adverse influences. [15][16][17] Therefore, researches on natural drugs may provide new ideas for the treatment of OS.…”

Section: Introductionmentioning

confidence: 99%

“…Recently, natural drugs have become a popular researching focus since drug discovery is a high‐risk and high‐cost process 10,11 . Evidence has suggested that several natural drugs, for example, vincristine, taxanes and camptothecin, are effective anti‐tumour agents 12‐14 . Furthermore, some natural compounds have been demonstrated to own anti‐tumour effects on OS cell lines with few adverse influences 15‐17 .…”

Section: Introductionmentioning

confidence: 99%

Proanthocyanidin B2 inhibits proliferation and induces apoptosis of osteosarcoma cells by suppressing the PI3K/AKT pathway

Zhou

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Osteosarcoma (OS) derived from bone-forming mesenchymal cells is the most common primary bone tumour in children and adolescents. 1-3 Among the OS patients, more than 90% are high-grade malignancies based on the grade of differentiation, and more than 20% have demonstrated significant metastasis lesions at the time of clinical diagnosis. 4,5 With the improvement of early diagnosis and treatment strategies, the 5-year survival rate of OS patients has increased up to 70%. 6 However, the long-term prognosis remains poor for the patients with advanced OS over the past 30 years mainly due to the resistance to chemotherapeutic agents, in addition to the metastatic

show abstract

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial

Cited by 63 publications

References 29 publications

Hypokalemia After Rituximab Administration in Steroid-Dependent Nephrotic Syndrome: A Case Report

Hypokalemia After Rituximab Administration in Steroid-Dependent Nephrotic Syndrome: A Case Report

From pathogenesis to personalized treatments of neuropathies in hematological malignancies

Proanthocyanidin B2 inhibits proliferation and induces apoptosis of osteosarcoma cells by suppressing the PI3K/AKT pathway

Contact Info

Product

Resources

About